• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Pear Therapeutics Inc.

    5/2/23 1:36:49 PM ET
    $PEAR
    Computer Software: Prepackaged Software
    Technology
    Get the next $PEAR alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-39969
    Issuer: Pear Therapeutics, Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 200 State Street, 13th Floor
    Boston MASSACHUSETTS 02109
    Telephone number: 617-925-7848
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Class A Common Stock and warrant
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-05-02 By Aravind Menon Hearings Advisor
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PEAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PEAR

    DatePrice TargetRatingAnalyst
    1/26/2022$5.00Neutral
    B of A Securities
    1/20/2022$11.00Outperform
    Credit Suisse
    1/3/2022$12.00Buy
    BTIG Research
    12/29/2021$13.00Buy
    Citigroup
    12/22/2021$16.00Buy
    Chardan Capital
    12/16/2021Outperform
    Cowen & Co.
    More analyst ratings

    $PEAR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process

      Pear Therapeutics, Inc. (NASDAQ:PEAR) ("the Company"), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the Company and its wholly owned subsidiary, Pear Therapeutics (US), Inc. (collectively, the "Debtors") each voluntarily filed for protection under chapter 11 ("Chapter 11") of the U.S. Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") and they intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code. Prior to the filing of the Chapter 11 cases, the Debtors evaluated a wide ra

      4/7/23 11:30:00 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

      MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

      4/3/23 4:05:00 PM ET
      $GLS
      $PEAR
      $SGHT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • 5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

      SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade. REZZAYO was developed by Cidara Therapeutics, Inc. (NASDAQ:CDTX), a company seeded and then supported by 5AM Ventures through its Series A and Series B rounds. 5AM's Scott Rocklage served as chair of the board of directors from the company's inception in 2012 through 2019. "Su

      3/23/23 10:19:01 AM ET
      $CDTX
      $ELVN
      $IMPL
      $PEAR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Computer Software: Prepackaged Software

    $PEAR
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Pear Therapeutics Inc.

      25-NSE - Pear Therapeutics, Inc. (0001835567) (Subject)

      5/2/23 1:36:49 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Pear Therapeutics, Inc. (0001835567) (Filer)

      4/10/23 4:36:29 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Pear Therapeutics, Inc. (0001835567) (Filer)

      4/7/23 11:32:19 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by 5am Partners Iv, Llc

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      4/12/23 4:51:37 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Snow Ellen

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:14:54 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Brenner Erin K.

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:14:18 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    Financials

    Live finance-specific insights

    See more
    • Pear Therapeutics Reports Third Quarter 2022 Results

      Grew revenue 24% quarter-over-quarter to $4.1 million Expanded patient access with new state and commercial payors Expanded real-world evidence with new peer reviewed publication Reduced quarter-over-quarter operating expenses and cut expected 2023 operating expenses Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its third quarter ended September 30, 2022. "Pear is making strong and steady progress toward our mission of making PDTs mainstream medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "

      11/14/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022

      Pear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third quarter 2022 financial results after the close of market on Monday, November 14, 2022. Management will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss the Company's financial and business highlights. To access the live conference call or webcast, participants should register online at https://investors.peartherapeutics.com/news-events/events-presentations. To avoid delays, we encourage participants to register fifteen minutes ahead of the

      10/31/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Reports Second Quarter 2022 Results

      20% quarter-over-quarter revenue growth to $3.3 million Recent real-world health economic data for all three of Pear's commercial products show cost-savings1-3 Recent commercial formulary additions for reSET® and reSET-O® Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its second quarter ended June 30, 2022. "Pear continues to make significant progress in introducing PDTs as an innovative class of medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "We believe our evidence generation strategy is de

      8/11/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    Leadership Updates

    Live Leadership Updates

    See more
    • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

      MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

      4/3/23 4:05:00 PM ET
      $GLS
      $PEAR
      $SGHT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • Jorge Gomez Joins Moderna as Chief Financial Officer

      CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel."I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee," said Mr. Bancel. "As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainabilit

      4/11/22 9:00:00 AM ET
      $CAH
      $MRNA
      $PEAR
      $XRAY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Computer Software: Prepackaged Software

    $PEAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B of A Securities initiated coverage on Pear Therapeutics with a new price target

      B of A Securities initiated coverage of Pear Therapeutics with a rating of Neutral and set a new price target of $5.00

      1/26/22 7:01:40 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Credit Suisse initiated coverage on Pear Therapeutics with a new price target

      Credit Suisse initiated coverage of Pear Therapeutics with a rating of Outperform and set a new price target of $11.00

      1/20/22 7:36:22 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • BTIG Research initiated coverage on Pear Therapeutics with a new price target

      BTIG Research initiated coverage of Pear Therapeutics with a rating of Buy and set a new price target of $12.00

      1/3/22 7:33:46 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13D/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      4/28/23 4:07:09 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13D/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      4/12/23 4:33:35 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13G/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      2/14/23 4:06:28 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology